

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic Item No	Checklist item	Line and page number in protocol
ADMINISTRATIVE INFORMATION		
Title:		
Identification	1a Identify the report as a protocol of a systematic review	1-2
Update	1b If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2 If registered, provide the name of the registry (such as PROSPERO) and registration number	76
Authors:		
Contact	3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	4-42
Contributions	3b Describe contributions of protocol authors and identify the guarantor of the review	360-364
Amendments	4 If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	304-305
Support:		
Sources	5a Indicate sources of financial or other support for the review	355-358
Sponsor	5b Provide name for the review funder and/or sponsor	N/A
Role of sponsor or funder	5c Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	N/A
INTRODUCTION		
Rationale	6 Describe the rationale for the review in the context of what is already known	102-134
Objectives	7 Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	136-139
METHODS		
Eligibility criteria	8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	149-154
Information sources	9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	206-217
Search strategy	10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	Additional file
Study records:		
Data management	11a Describe the mechanism(s) that will be used to manage records and data throughout the review	227-271
Selection process	11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	227-217
Data collection process	11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	227-245
Data items	12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	234-245
Outcomes and prioritization	13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	156-204

Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	247-252
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	256-257
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	257-271
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	273-287
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	N/A
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	289-295
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	301-302

From: Shamseer L, Moher D, Clarke M, Ghera D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*. 2015 Jan 2;349(jan02 1):g7647.